Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7285643 | 0.80 | PTGDR2 (0.50) | PTGDR2ALOX15LMNAALDH1A1THRA | |
| SCHEMBL3138757 | 0.79 | ALOX15 (0.50) | ALOX15LMNAALDH1A1THRATHRB | |
| SCHEMBL3453355 | 0.79 | LMNA (0.52) | PTGDR2ALOX15LMNATHRATHRB | |
| SCHEMBL8791845 | 0.79 | HPGD (0.57) | ALOX15LMNAALDH1A1THRATHRB | |
| SCHEMBL4416927 | 0.79 | MCL1 (0.50) | PTGDR2ALOX15LMNAALDH1A1THRA | |
| SCHEMBL21111524 | 0.78 | PSEN1 (0.41) | LMNAALDH1A1HPGD | |
| SCHEMBL28645298 | 0.76 | ALOX15 (0.65) | ALOX15LMNAALDH1A1THRATHRB | |
| SCHEMBL7282417 | 0.76 | ALOX15 (0.50) | PTGDR2ALOX15LMNAALDH1A1THRA | |
| SCHEMBL28090412 | 0.74 | PTPN7 (0.58) | ALOX15LMNAALDH1A1PKMPTPN7 | |
| SCHEMBL27261303 | 0.73 | PRKDC (0.43) | LMNAALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870616-B2 | Derivatives of sobetirome | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3457851-A1 | DERIVATIVES OF SOBETIROME | Oregon Health & Science University (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201320-A1 | DERIVATIVES OF SOBETIROME | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870616-B2 | Derivatives of sobetirome | SNCA, SLC6A3, SLC6A1 | PTGDR2 806/4885ALOX15 3055/4885LMNA 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.